Summary#
This bill creates a new precision oncology program for prostate cancer inside the Department of Veterans Affairs (VA). It requires the VA to set up a network of centers of excellence, a program leadership team, a national registry, and a telemedicine tumor board. The aim is to expand genetic testing, research, and clinical trials for veterans with prostate cancer and to coordinate care across VA facilities.
- Main change: Adds a new law requiring the VA to establish and run a precision oncology program for prostate cancer and to designate at least 21 centers of excellence (one in each Veterans Integrated Service Network).
- Who is eligible: Any veteran with a diagnosis of prostate cancer.
- Core services required at centers: genetic sequencing for advanced prostate cancer, a uniform sequencing platform, metastasis biopsy capability, clinical trials (including biomarker-specific trials), telemedicine tumor board participation, and a registry to track mutations and outcomes.
- Program leadership: A leadership team based at the Seattle VA Medical Center must include an Executive Director, Clinical Director, and Research Director with specified duties.
- Reporting and oversight: Annual reports to Congress are required. Formal performance reviews of centers start in 2030. The Secretary may add or, after notice, terminate center designations.
- Funding authorized: $15.5 million per year for fiscal years 2027–2029.
What it means for you#
-
Veterans with prostate cancer
- If you are a veteran diagnosed with prostate cancer, you become eligible to participate in the VA’s new precision oncology program.
- The program could give you access to genetic sequencing (especially for advanced cases), trials that match treatments to genetic markers, telemedicine tumor boards for case reviews, and travel support to reach studies.
-
Patients at VA medical centers
- Veterans near one of the designated centers may get easier access to advanced testing and specialized trials.
- Veterans near affiliated or supported facilities could get outreach or services extended from the centers.
-
VA clinicians and researchers
- Designated centers must hire or assign a specific minimum staff mix (medical oncologist, interventional radiologist, urologist, radiation oncologist, pathologist, and two research staff).
- Clinicians may take part in national research, monthly calls, in-person meetings, and mentorship programs to develop trials and research capacity.
-
Researchers and industry partners
- The program will coordinate with industry and the National Cancer Institute for study design and participation.
- Industry-sponsored studies and biomarker-specific trials are explicitly included.
-
Local VA networks and hospitals
- Each of the VA’s regional networks must have at least one center. Centers must help affiliated facilities in their region.
-
Taxpayers
- The bill authorizes federal funding for the program for three fiscal years; longer-term funding is not specified in the bill text.
Expenses#
Estimated public cost: The bill authorizes $15,500,000 for each of fiscal years 2027 through 2029.
- Direct authorization: $15.5 million per year for FY2027, FY2028, and FY2029 to carry out the program.
- Additional or ongoing costs: The bill requires centers, staffing, sequencing platforms, a registry, travel support, trial development, and program leadership. The text does not provide cost estimates for those items beyond the three-year authorization.
- Implementation plan requirement: The VA must submit a plan within 180 days that includes anticipated funding levels for a 10-year period. That plan would be the source for longer-term cost estimates.
- Fiscal note: No detailed cost breakdown or fiscal note is included in the bill text provided here.
No publicly available information beyond the authorization amounts is included in the bill text.
Proponents' View#
The bill appears intended to do the following:
- Improve access to precision (genomic) testing and targeted treatments for veterans with prostate cancer by creating a coordinated VA program.
- Build a network of dedicated centers so expertise, trials, and advanced testing are available in each VA region.
- Create a national registry and data repository to track mutations, outcomes, and survival. This could help match patients to trials and improve research.
- Encourage collaboration between VA clinicians, researchers, the National Cancer Institute, and industry to start and run biomarker-driven trials.
- Support decentralized and hybrid trial models (including telemedicine and remote coordination) to make trials easier to join.
Opponents' View#
The bill text raises several questions and possible concerns:
- Funding beyond 2029 is not set in the bill. One concern is whether the program can be sustained after the three years of authorized funding.
- The authorized $15.5 million per year may be small compared to the likely total cost of staffing, sequencing platforms, biopsies, travel support, registry maintenance, and trial operations. The bill does not provide a detailed fiscal estimate.
- The bill names an initial set of centers and makes Seattle the site of program leadership. Some may worry this centralization could affect how resources and decisions are distributed.
- The sequencing activities in the bill focus on “advanced” prostate cancer but eligibility covers all diagnosed veterans. It is unclear how services will be prioritized or which veterans will receive sequencing and trials.
- Performance reviews do not start until 2030. That delay could leave program quality and effectiveness unmeasured for several years.
- The bill allows participation in industry-sponsored studies and industry partnerships. The bill does not detail safeguards about conflicts of interest, data sharing, or patient protections in those partnerships.
- The bill requires specific staff at each center. Hiring and retaining specialized staff at all centers may be difficult, especially in areas with workforce shortages.